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INTRODUCTION
On  a  global  basis,  primary  liver  cancer  which  is  almost  entirely 
hepatocellular carcinoma  constitutes approximately 5.6% of cancers and in some 
populations is the most common cancer1,2.  The largest numbers of cases are found 
in  Asia  (76%  of  all  hepatocellular  carcinoma),  followed  by  Africa.   Annual 
incidence  rates  for  hepatocellular  carcinoma  are  below  5  cases  per  1,00,000 
population in North and South America, North and Central Europe and Australia 
with intermediate rates of upto 15 cases per 100,000 in countries bordering the 
Mediterranean. The highest annual incidence rates are found in Korea, Taiwan, 
Mozambique  and Southeast  China,  approaching 36 per  100,000.   Within  each 
geographic area (low or high incidence), blacks have attack rates approximately 
threefold higher than Caucasians.  
In India, it is estimated that there are approximately 2 – 2.5 million cases of 
cancer at any given point of time, with around 7,00,000 new cases being detected 
each  year.  Nearly  half  of  these  cases  die  each  year3.  The  incidence  of  liver 
malignancy is about 5.6 percent4 and among the top three causes of death from 
cancer are included the cancer of lung (17.8% of all deaths), stomach (10.4%) and 
liver (8.8%)4. In India, the National Cancer Registry Programme of the   ICMR 
provides  data  on  incidence  from  five  population  based  registries.  The  age 
standardized cancer incidence at Mumbai in India for liver, was 4.9 per 1,00,000 
in males and 2.5 per 1,00,000 in females3. 
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Worldwide, there is a clear predominance of males, ranging from 1.5:1 in 
countries with a low incidence of hepatocellular carcinoma to approximately 3:1 in 
populations with a high frequency.  More than 85% of cases of hepatocellular 
carcinoma occur in countries with high rates of chronic hepatitis B viral infection 
incidence.5 
There is strong evidence of a pathogenetic role of hepatotropic viruses in 
the  development  of  liver  cell  carcinoma,  not  only  through  the  causation  of 
cirrhosis but also in non - cirrhotic livers6,7.  This is true for both hepatitis B and 
hepatitis C viruses and for both adult and pediatric patients8.
In one series from Japan, the development rate of hepatocellular carcinomas 
after a 15-year observation period was 27% in hepatitis B and 75% in hepatitis C9. 
The incidence of hepatitis B and / or hepatitis C surface antigenemia in patients 
with liver  cell  carcinoma is  over  90%, both in  the  United States  and in  other 
countries10,11 In  patients  with  hepatitis,  increased proliferative  indices  and high 
alpha - fetoprotein serum value represent risk markers for liver cell carcinoma12,13.
Serum  alpha  -  fetoprotein  levels  remain  the  most  useful  marker  for 
hepatocellular carcinoma .  Serum alpha - fetoprotein levels are elevated (>10 to 
20 ng/ml) in about 70% to 80% of patients (specificity, 90%) with hepatocellular 
carcinoma.  It is frequently detectable at levels greater than 200 ng/ml in HBV 
related and HCV related cases ( ~ 76%); however, tumors arising in the context of 
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alcohol related cirrhosis (65%),  those found in the non cirrhotic liver (33%), and 
those  less  than  2  cm  in  diameter  (25%)  less  often  show  elevations  of  this 
magnitude, and serum alpha - fetoprotein may even be undetectable in all these 
cases14.
Guided fine needle aspiration biopsy is increasingly being recognized as an 
excellent  diagnostic  method  for  detecting  hepatic  malignancy15.  Fine  needle 
aspiration has several advantages over thick needle biopsies : 
a. Multiple  aspirations  can  safely  be  performed  to  ensure  an  adequate 
specimen.
b. Specimen adequacy can be checked and immediate interpretation of the 
material is possible.
c. Left lobe, porta hepatis can be reached and can be performed in patients 
with ascites, portal hypertension or obstructive jaundice.
d. Implantation of malignant cells along the needle tract appears to be less 
common than with thick needle biopsy.
Therefore, for any mass or masses in the liver suspected to be malignant, 
guided fine needle aspiration  cytology is the method of choice16. The sensitivity of 
guided  fine  needle  aspiration  cytology  for  a  diagnosis  of  hepatic  malignancy 
ranges from 90% to 96% with a specificity of 90% to 100%17.  The application of 
immunocytochemical technique further enhances diagnostic accuracy in the typing 
of hepatic cancers. 
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Immunocytochemistry on fine needle aspiration smears is both a science 
requiring  specialized  training  and  an  art  demanding  dedication  and  nurture. 
Immunocytochemistry has the potential of transforming surgical pathology from a 
subjective “art” to an objective “science” based on the way cells can be recognized 
by microscopic methods.  Given the choice of vast array of antibodies that can be 
used in immunocytochemistry, the problem lies in choosing wisely.
High serum levels  of  alpha -  fetoprotein provide strong support  for  the 
diagnosis of hepatocellular carcinoma.  Therefore serologic tests and a detailed 
clinical history are important, especially in difficult cases.  
12% to 62% of  hepatocellular carcinomas are positive for alpha-fetoprotein 
in   immunocytochemistry17.   Hence,  a  positive  immunocytochemistry  result 
strongly supports the diagnosis of hepatocellular carcinoma, but a negative result 
does not exclude hepatocellular carcinoma19.
The purpose of this study is to determine whether alpha - fetoprotein could 
be used to aid in the diagnosis of hepatocellular carcinoma and also to evaluate the 
distribution  of  alpha  -  fetoprotein  in  hepatocellular  carcinomas  of  varying 
differentiation. 
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AIMS AND OBJECTIVES
1. To assess the percentage positivity of cytological expression of alpha - 
fetoprotein  in fine needle aspiration smears of hepatocellular 
carcinoma .
2. To  correlate  the  percentage  positivity  of  cytological  alpha  -  fetoprotein 
expression and serum alpha - fetoprotein level with the differentiation of 
hepatocellular carcinoma.
3. To correlate the incidence of hepatocellular carcinoma with hepatitis B and 
hepatitis C viral infections.
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REVIEW OF LITERATURE
 Hepatocellular carcinoma, a unique human neoplasm, has interested 
many in several fields of biological and health sciences. This cancer is 
credited as the first that could be largely eliminated by a safe anti-viral 
vaccine, the hepatitis B vaccine. It is also the first cancer for which a reliable 
diagnostic tumour marker – alpha - fetoprotein  was identified. Also studies 
on this tumour in humans and animals have provided a large body of 
information on causation and stepwise evolution of cancers. Being a common 
and rapidly fatal tumour, mainly affecting males in the more populous 
developing countries, hepatocellular carcinoma may well be the commonest 
cancer of the human males20.
GLOBAL INCIDENCE AND DISTRIBUTION:
Hepatocellular carcinoma constitutes about 85% of primary liver 
cancer recorded in cancer data banks and records. It is the fifth most 
common neoplasm in the world and the third most common cause of cancer 
related death (21)
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    Incidence and mortality of five most common cancers world wide, 200021.
Site Number of Cases (Incidence%)
Number of deaths 
(Mortality %)
Lung    1238.9      (12.3%)   1103.1   (17.7%)
Breast 1050.3     (10%)           373       (6%)
Colorectum   944.7      (9.4%)           492.4    (7.9)
Stomach 876.3      (8.7%)     646.6   (10.4%)
Liver    564.3      (5.6%)     548.6   (8.8%)
Total 10,055.6     (100%)  6208.7   (100%)
Globally, around 5,00,000 new cases are diagnosed yearly, with an age 
adjusted world wide incidence of 5.6 to 14.9 per 1,00,000 population.. It 
accounts for 5.6% of all human cancers with incidence greater in males 
(7.5%) than in females (3.2%).Almost the same number die of this cancer 
annually21
PREDISPOSING AND ASSOCIATED FACTORS : 
Hepatotropic viruses, both hepatitis B and hepatitis C virus are 
believed to be causally associated in the development of hepatocellular 
carcinoma.
HEPATITIS B VIRUS & HEPATOCELLULAR CARCINOMA :
HBV is a member of hepadna virus group and is a double stranded 
DNA virus that replicates by reverse transcription. It is a 42 nm particle 
comprising an electron dense core (nucleocapsid) which is 27 nm in diameter 
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and an outer envelope of the surface in membranous lipid derived from the 
host cell.
Markers of viral replication in serum include HBV DNA, the surface 
protein HBsAg, and a soluble antigen HBeAg which is secreted by infected 
hepatocytes. HBsAg is detectable by radio immunoassay or enzyme 
immunoassay. Enzyme immunoassay is specific and highly sensitive and is 
used in preference to radio immunoassay.
The antigen persists during the acute phase of the disease and sharply 
decreases when antibody to the surface antigen becomes detectable. The virus 
persists in approximately 5 – 10% of immunocompetent adults and in as 
many as 90% of infants infected perinatally. Persistent carriage of HBV is 
defined by the presence of HBs Ag in the serum for more than 6 months and 
it has been estimated to affect about 3,50,000,000 people worldwide22.
A number of studies have shown a relationship between persistent or 
past infection with HBV and the eventual development of hepatoma especially 
in areas of the world where the prevalence of HBV is high. It is noteworthy 
that the frequency of hepatoma follows the same geographic pattern of 
distribution as that of persistent HBV infection. The frequency of finding 
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HBsAg in hepatoma patients is significantly higher than in controls living in 
the same region.
Although there  are  millions  of  HBV carriers  in  the  world,  hepatoma is 
relatively uncommon. This situation is not unusual in viral infections. The risk 
factors other than exposure to HBV which are associated with development of 
hepatoma are not known, but age when first infected appears to be important22.
Once  infected  with  HBV,  males  are  more  likely  to  remain  persistently 
infected, whereas females are more likely to be transiently infected and to develop 
anti HBs. More males than females develop cirrhosis of the liver (by a ratio of 3:1) 
and an even greater proportion develop liver cancer (by a ratio of 6:1). Thus at 
each progressive stage of liver disease the ratio of males to females appear to 
double  so  that  hepatocellular  carcinoma  becomes  predominantly  a  disease  of 
male23.
In a prospective study by Bearley et al among 22, 707 Oriental males in 
Taiwan followed for an average of 6.2 years, the risk of developing hepatocellular 
carcinoma proved to be 217 times greater for the HBsAg carriers than for the non 
carriers. An overall average of one hepatoma death per 322 HBsAg carriers per 
year has been observed. This translates to approximately 0.3% deaths from liver 
cancer per year among male Oriental carriers. Thus it can be estimated that the risk 
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of developing primary liver cancer in an Oriental HBsAg positive carrier during a 
50 years surveillance period is about 15%23.
In a recent study involving almost 11,000 men in Taiwan, positivity for 
HBeAg was found to be definitely associated with an increased risk for 
the development of hepatocellular carcinoma. Both surface and core 
antigens can be detected by immunohistochemistry in the cytoplasm of 
the tumor cells and the non neoplastic hepatocytes in many of the 
cases. Integration of hepatitis virus DNA into the genome of the 
tumour cells has also been documented. The PCR technique can 
demonstrate transcriptionally active HBV genomes among patients 
with liver cell carcinoma who are negative for HBsAg12. 
Possible consequences of hepatitis B virus infection in an adults  23  
            
Acute HBV infection
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negative in 
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persistent 
hepatitis 
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HEPATITIS C VIRUS AND HEPATOCELLULAR CARCINOMA :
HCV is an enveloped single stranded RNA virus 30 – 60 nm in size that 
is related to flavi viruses. ELISA can be used to detect anti HCV antibodies. 
Positive reactions by ELISA require confirmation by immunoblot assay. 
Most acute infections with HCV are asymptomatic and about 20% of acute 
infections cause jaundice and fulminant hepatitis. Current data suggest that 
about 80% of infection with HCV progress to chronicity.
Histological examination of liver biopsies from asymptomatic HCV carriers 
has revealed chronic active hepatitis, cirrhosis or both in upto 70%. Infection with 
HCV is also associated with progression to primary liver cancer. 
In  Japan,  where  the  incidence  of  hepatocellular  carcinoma  has  been 
increasing despite a decrease in the prevalence of HBs Ag, it is believed that HCV 
is a major risk factor22. Hepatocellular carcinoma, in developing countries affect 
young  patients  with  chronic  hepatitis  B  virus  infection  whereas  in  developed 
countries it appears in older patients related to hepatitis C virus infection21.
Cirrhosis, liver cell dysplasia (including both large cell dysplasia and small 
cell  dysplasia),  adenomatous  hyperplasia  are  the  lesions  associated  with  high 
incidence of hepatocellular carcinoma. Other etiological agents include Aflatoxin, 
Thorium dioxide exposure,  Androgenic anabolic  steroids,  Progestational  agents 
and Alpha 1 – antitrypsin deficiency12. 
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Pathway of carcinogenesis : 
A stepwise carcinogenesis for hepatocellular carcinoma has been 
proposed on the basis of gradually increasing size and cellular density among 
hepatocellular lesions. According to the currently used terminology, the 
stepwise sequence of events can be translated as follows :
Several authors have proposed a de novo pathway, a single cell or a group 
of hepatocytes may give rise to a focus of small hepatocellular carcinoma that will 
grow into a large hepatocellular carcinoma 24. 
MACROSCOPIC TYPES OF HEPATOCELLULAR CARCINOMA : (12)   
Grossly, liver cell carcinoma may present in one of the following forms.
1. Single mass -     Solitary
2. Multiple Nodules       -     Multinodualr 
3. Diffuse Lesion       -     Diffuse
4. Large mass in the liver  -     Massive form.
HISTOLOGIC GRADING OF HEPATOCELLULAR CARCINOMA :
The histologic  grading to  tumor differentiation is  assigned by using the 
Edmondson grading system(24, 25).
Grade I
 Cells similar in size to normal hepatocytes
 Arranged in relatively thin trabeculae
 Areas containing bile are rare
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Grade II
 Cells  are larger  than normal  hepatocytes with more hyperchromatic 
nuclei which occupy a higher proportion of cells.
 Trabeculae are thicker.
 Acini with bile are common.
Grade III
 Hepatocytes  with  larger  nuclei,  occupying  more  than  50%  of  the 
cytoplasm.
 Trabeculae are still dominant, but solid areas and isolated cells may 
also be present.
 Giant cells common.
 Bile is rarely present.
Grade IV
 Cells with nuclei occupying most of the cytoplasm, and the cytoplasm 
may not be eosinophilic.
 Mostly solid areas are found.
 Bile is rarely found.
 Intravascular and intrasinusoidal growth is common.
 Includes spindle cell and small cell components.
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 With the above grading system, grade I cell populations may be difficult to 
distinguish from hepatocellular adenomas, and grade IV cell populations may be 
difficult to distinguish from tumors of nonhepatocellular origin(22, 23).
HEPATOCELLULAR CARCINOMA IN CYTOLOGY :
Hepatocellular  carcinoma  is  the  most  common  primary  hepatic 
malignancy(19). Fine needle aspiration cytology is still considered as a necessary 
procedure for diagnosing hepatocellular carcinoma.
DEFINITION OF CYTOLOGICAL CRITERIA :25
1. High cellularity - Cellular material covering 50% of atleast one slide.
2. Increased nuclear size -  Nuclei  more than twice the diameter  of  a  normal 
hepatocyte nucleus.
3. Increased N : C ratio - Ratio more than 1:4 (Normal hepatocyte ratio 1:5)
4. Macronucleolus - Easily visible at x250
5. Increased mitoses - More than 1/20 high power field.
6. Nuclear atypia - Hyperchromasia and irregular nuclear membrane.
7. Large fragments -  Microbiopsies, usually with central vessels and / or more 
than 100 cells.
8. Intermediate sized clusters - More than 10 or less than 100 cells.
9. Small groups - 4 – 10 cells.
10. Widened Trabeculae - More than 2 cells thick.
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 The  cytologic  appearance  of  hepatocellular  carcinoma  varies  with  the 
degree of differentiation.  The cytologic diagnosis of hepatocellular carcinoma can 
be separated into two main categories, that is, low grade (well-differentiated) and 
high grade tumors (moderate and poorly differentiated)19.
Cytological  appearance  of  low  grade  hepatocellular  carcinoma  (well 
differentiated) :19
1. Low  power  smear  pattern  with  smooth-edged  clusters  and  thickened 
trabeculae  with  peripherally  wrapped  endothelial  cells  (virtually 
pathagnomonic)
2. Low power smear pattern with more than focal, loosely cohesive sheets of 
hepatocytes with transgressing vessels (highly suspicious finding).
3. Monotonous  uniform  hepatocytic  cell  population  with  subtle  malignant 
features.
4. Acinar cell formation in clusters.
5. Increased N:C ratio compared with normal hepatocytes.
6. Macroeosinophilic nucleoli.
7. Reduced number of binucleated cells. 
8. Absence of epithelial cells.
9. Reticulin stain on cell block demonstrates reticulin loss and loss of the normal 
hepatic plate architecture (e.g. ≥  3 cells thick).
10. Iron stain fails to stain tumour in cases of haemochromatosis.
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Cytological appearance of high-grade hepatocellular carcinoma (moderate & 
poorly differentiated) :19
1. Peripherally wrapping endothelial smear pattern is virtually pathagnomonic.
2. Transgressing  vessels  are  suggestive  but  cannot  distinguish  hepatocellular 
from renal cell carcinoma.
3. Presence of intracytoplasmic bile is pathagnomonic.
4. Polygonal  cells  with  central  nuclei  and  prominent  nucleoli  with  visible, 
granular to clear cytoplasm in moderately differentiated tumors ; scant to no 
cytoplasm in poorly differentiated tumors.
5. Immunophenotype  Low  molecular  weight  cytokeratin,  Polyclonal  CEA  , 
CDIO (canalicular) and  HepPar-1 are positive. High MW cytokeratin (AE1) is 
usually negative.
 The  diagnosis  of  moderately  differentiated  hepatocellular  carcinoma  is 
usually straightforward because they look like normal liver while at the same time 
demonstrating obvious malignant features.  At one end of spectrum, the tumor is 
well differentiated and it resembles liver and is difficult to distinguish from benign 
and reactive hepatocytic nodules.  While at the other end of spectrum the tumor is 
poorly differentiated and  is obviously malignant but may be difficult to appreciate 
its hepatic origin and to differentiate it from metastatic deposits in the liver. 
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Differentiation  between  well  differentiated  hepatocellular  carcinoma  and 
benign hepatic lesions :(27)
Benign hepatocytic nodules and mass lesions include
1. Macro regenerative nodule
2. Dysplastic nodule
3. Focal nodular hyperplasia
4. Hepatocellular adenoma
 They are all discussed together because they share many cytologic features 
and distinction between them on cytology alone is not possible.
Cytologic features of Benign and Reactive Hepatocytic Nodules :19
1. Variably cellular smear (but not densely cellular).
2. No peripherally wrapping endothelial cells.
3. Clusters may have transgressing endothelial cells.
4. Mild pleomorphism of cell and nuclear size, sporadically placed  large, 
atypical cells (dysplastic hepatocytes / large cell change).
5. Many binucleated hepatocytes.
6. Variably prominent nucleoli but no macro eosinophilic nucleoli.
7. Cytoplasm  is  generally  abundant  and  granular  but  may  show  fatty 
change, lipofuscin pigment, or iron deposition.
8. Reticulin stain reveals retained framework of one or two cell layers on 
cell block.
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 One very helpful clue for well differentiated hepatocellular carcinoma 
is the presence of one of the two characteristic endothelial patterns.
1.  Basketing  endothelial cells wrap groups or trabeculae. This pattern is 
seen in   
      50% of hepatocellular carcinoma but is specific for  hepatocellular 
carcinoma.    
      This pattern is seldom seen in benign hepatic lesions or other 
malignancies. 
2. Traversing capillaries through groups of hepatocytes. This pattern is 
noted in over 90% of hepatocellular carcinoma but is less specific than the 
“basketing” pattern since it can be seen in other malignancies and rarely, 
some non-neoplastic liver conditions. 
Acinar formation and the presence of prominent "cherry red"  nucleoli 
favour well differentiated hepatocellular carcinoma. Ancillary studies may be 
helpful in differentiating benign and neoplastic hepatocytes. Decrease or 
absent reticulin staining or positive staining pattern outlining trabeculae 
greater than three cells thickness support the diagnosis of hepatocellular 
carcinoma.
Others have shown that the diffuse immunostaining with CD34 and 
factor VIII also favor hepatocellular carcinoma. Positive alpha - fetoprotein 
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staining is reported in 40% of hepatocellular carcinoma, but negative staining 
does not rule out a diagnosis of hepatocellular carcinoma (19). 
Differentiation between high grade hepatocellular carcinoma and metastatic 
adenocarcinoma:27     
In many instances, a known history of primary tumor is available and 
the task is to determine whether the morphology of the liver lesion is 
compatible with that of the known primary tumor. However, when a history 
is not available, the questions that  need to be addressed will be “ is it 
primary?” or “is it metastatic?”. A markedly elevated serum alpha - 
fetoprotein  level and the finding of a single lesion with or without satellite 
lesions on imaging favour a primary tumor over a metastatic disease.
Cytologically, bile production as evidenced by the presence of bile in 
the cytoplasm of malignant cells or in canaliculi between malignant cells, is 
considered diagnostic of hepatocellular carcinoma. Unfortunately bile is 
present in only half of the cases.
Although the “basketing” endothelial pattern is pathagnomonic for 
hepatocellular carcinoma, it is often absent in poorly differentiated turnours. 
The presence of “traversing” capillaries is less specific and can be seen in 
some metastatic lesions , particularly renal cell carcinoma. The key in 
diagnosing a poorly differentiated hepatocellular carcinoma is to look for 
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better differentiated cells with more typical hepatocytic features. 
Immunocytochemistry is of little help in differentiating  poorly differentiated 
hepatocellular carcinoma from metastatic lesions because of a lack of highly 
specific markers. 
Canalicular staining pattern with antibodies against polyclonal 
carcinoma embryonic antigen (pCEA)  and diffuse positive staining with 
endothelial cell markers (such as CD 34, factor VIII) can help distinguishing 
hepatocellular carcinoma from metastatic adenocarcinoma. But positive 
staining with these markers is least often identified in poorly differentiated 
hepatocellular carcinoma.
Another relatively new marker HepPar I, has been shown to be quite 
specific and sensitive as a marker for hepatocellular carcinoma. About 83% 
to 100% of hepatocellular carcinoma stained positive with HepPar I but only 
4% to 15% of metastatic carcinomas were positive. Unfortunately, only 56% 
of poorly differentiated hepatocellular carcinoma expressed HepPar 1(27).
ALPHA - FETOPROTEIN :
History:
Alpha - fetoprotein  was first identified in human fetal sera by Bregstrand & 
Czar in 1956 on paper elecrophoregrams. Tatarinov demonstrated embryo-
specific Alpha-globulin in the serum of patients with hepatocellular 
carcinoma .A few years later, it became clear that alpha - fetoprotein  is a 
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valuable marker in the differential diagnosis of hepatocellular carcinoma. 
Moreover, it was found during clinical studies that alpha - fetoprotein  is also 
associated with teratoblastoma of the testis and ovarian germ cell tumors.
Several  highly  sensitive  methods  of  alpha  -  fetoprotein   detection  were 
elaborated in the early 1970’s,but the most practical one was found to be Radio 
Immuno  Assay  (RIA)  first  introduced  by  Ruoshlati  and  Seppala.  This  assay 
permitted the detection of  alpha - fetoprotein  from its background level to its 
maximal values in different pathologies. Later, RIA was supplanted by enzyme-
linked immunosorbent assay(ELISA) which is identical to RIA in specificity and 
sensitivity but more stable and ecologically acceptable.
Biology of alpha - fetoprotein  ontogeny :
Alpha -  fetoprotein is  an embryo-specific  alpha-globulin that  is  a  major 
component  of  early  embryonal  serum  in  mammals.  The  amount  of  alpha  - 
fetoprotein  in embryonal serum is higher than the initial level of serum albumin, 
a  predominant  protein  of  late  fetal  and  adult  sera.  The  synthesis  of  alpha  - 
fetoprotein  is initiated with embryonal hematopoeisis in the yolk sac, particularly 
in the yolk sac visceral endoderm (YSVE).The YSVE is the site of synthesis of all 
serum proteins  in  the  early  embryonic  development  including  serum albumin, 
alpha  1-antitrypsin,   transferrin  and  early  alpha  -  fetoprotein  .  Later,  when 
embryonal hematopoeisis is replaced by fetal hematopoeisis, in which the liver 
becomes the main site of blood formation, the synthesis of alpha - fetoprotein  and 
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the  other  serum proteins  is  transferred  to  the  liver.  Trace synthesis  of  alpha - 
fetoprotein  is also noted in the fetal gut, as the YSVE, fetal gut and liver are 
closely related developmentally.
 Alpha - fetoprotein  is an obligatory component of embryonal and fetal 
hematopoeisis  but  little  if  anything  is  known  regarding  the  nature  of  the 
association whether it is functional, includes common regulatory links, or is only 
coincidental28.
Alpha - fetoprotein structure and function :
The structure of alpha - fetoprotein  has been relatively well - characterised. 
It  is  a  glycoprotein  with  a  small  (approximately  4%)  carbohydrate  moeity 
represented  by  one  oligosaccharide  residue.  The  protein  moeity  has  been 
completely determined, consisting of one polypeptide chain of 590 amino acids 
arranged  in  three  well  defined  domains,  with  a  total  molecular  weight  of 
approximately 69,00029.
Regulation of Alpha - fetoprotein  Expression at the Cellular Level:
The  developmental  regulation  of  alpha  -  fetoprotein   synthesis  and  the 
reasons for its reappearance in malignancy are among the most avid areas of alpha 
- fetoprotein  research.  The first site of alpha - fetoprotein  synthesis is the earliest 
differentiated  embryonic  structure,  the  YSVE.  This  was  shown  by 
immunohistochemical methods and by direct demonstration of alpha - fetoprotein 
synthesis in tissue culture. It is very important to note that even in this tissue alpha 
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-  fetoprotein   synthesis  in  not  constitutive  but  regulated  by  intercellular 
interactions.
Alpha -  fetoprotein  is  detected from the very  onset  of  liver formation, 
produced by all hepatocytes in the liver bud, and continues to be expressed in mice 
and rats up to delivery and in human fetuses up to the second half of pregnancy. 
The decline of alpha - fetoprotein  production coincides with the formation of the 
definitive liver plates, which are seen well in postnatal mice and rats. This decline 
begins in the portal area and moves in a gradient like manner to the central veins. 
The bright  ring of  alpha -  fetoprotein positive cells  persists  around the central 
veins up to the complete cessation of its synthesis. It should be emphasised that 
hepatocyte proliferation per se is not responsible for alpha - fetoprotein  synthesis, 
as alpha - fetoprotein  synthesis may be resumed in non proliferating liver cells, as 
well as remain dormant in proliferating tissue.
The inhibition of alpha - fetoprotein  synthesis appears reversible in all or at 
least most hepatocytes. It is demonstrated that alpha - fetoprotein  synthesis in 
mature  hepatocytes  is  reversibly  repressed  under  the  influence  of  intercellular 
interactions.  The  nature  of  this  crucial  interaction  and  the  pathway  from 
intercellular contact to specific gene activation currently await further  study.
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Because not all hepatocellular carcinoma produce alpha - fetoprotein , 
its presence is not essential to hepatocellular  carcinogenesis and there is no 
evidence that tumours that do not produce alpha - fetoprotein  are 
biologically different from the majority of hepatocellular carcinoma. 
Synthesis of alpha - fetoprotein  by a tumour is permanent and  age related 
.The younger the patient, the more likely the serum value is raised and the 
higher the level attained, provided that patients are age-matched. There is no 
sex difference in alpha - fetoprotein  production. No obvious correlation exists 
between the serum concentration of alpha - fetoprotein  and any of the 
clinical or biochemical features of the tumor or the survival time after 
diagnosis. However, small presymptomatic tumours are associated with an 
appreciably lower serum levels of alpha - fetoprotein  than are symptomatic 
tumours. Attempts to correlate the degree of differentiation of hepatocellular 
carcinoma with the production of alpha - fetoprotein  have produced 
conflicting results30.
Because both false positive and false negative  results are obtained 
when alpha - fetoprotein  is used as a serum marker for hepatocellular 
carcinoma the research for  an ideal tumour marker continues. A number of 
alternative markers have been suggested although none has proved to be 
more useful than alpha - fetoprotein 30. 
30
Alpha - fetoprotein  in hepatocellular carcinoma of varying differentiations :
With  hepatocellular  carcinoma,  despite  a  relatively  high  incidence  of 
increased alpha - fetoprotein  levels of up to 70-80% over the background level, 
the correlation of increased alpha - fetoprotein  levels of pathological grade is less 
clear. 
1. The overall tendency is for resumed alpha - fetoprotein  production in poorly 
differentiated  tumours  and  for  its  absence  in  highly  differentiated 
hepatocellular carcinoma. However,  many exceptions exist, including  loss of 
alpha - fetoprotein  production by strongly alpha - fetoprotein positive tumour 
strains even without any visible changes in the degree of differentiation.
2. Large heterogeneity of alpha - fetoprotein content within an alpha - fetoprotein 
positive tumor, such that it is possible to isolate alpha - fetoprotein  producing 
and non producing clones from the same tumor, demonstrating the reversibility 
of this trait.
3. In moderately differentiated hepatocellular carcinoma there is absence of 
correlation between cell morphology and alpha - fetoprotein production28.
Clear  and  unequivocal  interpretation  of  alpha  -  fetoprotein   levels  in 
hepatocellular  carcinoma requires  a  knowledge  of  the  precursor  cells  of 
hepatocellular carcinoma, as well as their alpha - fetoprotein  status. The so called 
oval cells, discovered in rat liver at the acute phase of hepatocarcinogen action and 
alpha - fetoprotein  production by these cells, became the first candidates for liver 
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stem  cells  or  their  close  progeny,  and  the  most  plausible  candidates  for 
hepatocellular  carcinoma precursor  cells.  Although  this  hypothesis  helped  to 
explain alpha - fetoprotein  production by hepatocellular carcinoma , there is no 
evidence that  a significant part of  hepatocellular carcinoma is derived from the 
oval cells28. 
It is possible that the hepatocyte, and not only its precursor may serve as a 
progenitor  of  hepatocellular  carcinoma.  Further  more,  the  state  of  the  mature 
hepatocyte is determined by intercellular and cell-matrix interactions and hence is 
dependent on matrix composition and the presence of receptors responsible for 
such interactions. The developmental regulation of alpha - fetoprotein  may be 
based on the appearance of putative receptors associated with the transition from 
hepatoblast  to hepatocyte with simultaneous formation of adequate matrix. Poorly 
differentiated  anaplastic  hepatomas  may  be  devoid  of  receptors,  while  highly 
differentiated  tumours  may  have  both  systems  unimpaired,  leading  to  alpha  - 
fetoprotein  suppression.  In  moderately differentiated  hepatocellular carcinoma, 
variations in matrix composition in a particular tumour and in different parts of the 
same tumor may in part explain the tremendous variation in alpha - fetoprotein 
production. Mutations and epigenetic events may further account for this variation. 
Clearly,  much  investigation  remains  in  order  to  advance  the  understanding  of 
alpha - fetoprotein production in hepatocellular carcinoma.
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Alpha - fetoprotein in other conditions :
Hepatoblastoma  is  a  distinct  entity  from  hepatocellular  carcinoma, 
consisting of hepatoblast like cells similar to embryonic liver parenchyma cells 
and secreting large amounts of alpha - fetoprotein  in upto 90% of tumours28.
In some 66% of men with testicular teratomas, elevated levels of alpha - 
fetoprotein are found and are usually associated with endodermal sinus tumour 
differentiation. Embryonal carcinomas can show alpha - fetoprotein positive cells, 
whereas pure seminomas, teratomas, and choriocarcinomas are negative for alpha 
-  fetoprotein.  Data  suggest  that  there  are  two  molecular  variants  of  alpha  - 
fetoprotein;  Conconavalin  A  reactive  and  Conconavalin  A  nonreactive.  The 
former is found predominantly in serum samples from patients with hepatocellular 
carcinoma and hepatoblastoma, and the latter is elevated in serum of patients with 
germ cell tumours31.
Ovarian  neoplasms  that  express  alpha  -  fetoprotein  include  yolk  sac 
tumours  and  tumours  showing  hepatoid  differentiation,  including  hepatoid 
carcinoma  and  metastatic  hepatocellular  carcinoma.  Among  germ cell  tumors, 
alpha -  fetoprotein expression is  almost entirely confined to yolk sac tumours, 
although focal expression can be seen in the rare embryonal carcinoma. Therefore 
alpha - fetoprotein expression in ovarian surface epithelial tumours is generally 
considered to be definitive  support  for a  yolk sac tumor given the appropriate 
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morphologic  context.  This  is  particularly  important  in  the  distinction  of  true 
endometrioid proliferations from the endomertrioid yolk sac tumour31.
Alpha  -  fetoprotein  producing  carcinomas,  hepatoid  or  otherwise,  are 
increasingly  being  recognized  at  extra  hepatic  sites.  Aileen   Wee  and  Anjula 
Thomas have reported two cases – one of gastric Adenocarcinoma with a liver 
mass  whose  hepatic  aspiration  revealed  an  alpha  -  fetoprotein  producing 
Adenocarcinoma and the other was an endocervical adenocarcinoma with multiple 
liver  nodules  whose  aspiration  revealed  an  alpha  -  fetoprotein  producing 
undifferentiated carcinoma32.
Alpha - fetoprotein producing carcinomas occur in extrahepatic sites like 
the lung, gastrointestinal tract, female genital tract and urinary tract. Some of these 
tumours have hepatoid morphology, prompting one to search for a hepatocelluar 
carcinoma  within the liver and to ascertain the serum alpha - fetoprotein levels 
and  tumour  immunoreactivity  for  alpha  -  fetoprotein31.   Alpha  -  fetoprotein 
producing carcinomas represent about 5% of gastric cancers and of these, hepatoid 
adenocarcinoma is the most frequently observed histologic type32.
Alpha - fetoprotein producing carcinomas of primary extra hepatic origin 
were  also  noted  in  cholangioma,  angiofibromyxoma,  oesophageal  malignancy, 
gastric  carcinoma,  duodenal  carcinoma,  colorectal  carcinoma,  pancreatic 
carcinoma and cervical carcinoma46.
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SERUM ALPHA - FETOPROTEIN LEVELS :
A sensitive radio immunoassay for alpha - fetoprotein   has been employed 
in  the  screening for  primary  hepatocellular  carcinoma.  About  70% to  90% of 
patients  with  hepatocellular  carcinoma  have  elevations  in  serum  alpha  - 
fetoprotein and significant elevations are also observed in patients with germ cell 
tumours, other gastro intestinal malignancies and non – neoplastic hepatitis ,viral 
and alcoholic hepatitis and primary biliary cirrhosis. To enhance the specificity of 
this test in the diagnosis of hepatocellular carcinoma, a minimum concentration for 
postivity of 400 ng/ml has usually been assumed although this arbitrary cut off 
may  exclude  upto  one  third  of  patients  with  biopsy  proven  hepatocellular 
carcinoma33.
A  recently  developed  monoclonal  radio  immunoassay  may  improve  the 
specificity of alpha - fetoprotein screenings. Levels of alpha - fetoprotein found in 
10 – 12% of hepatocellular carcinoma cases are below the specificity threshold of 
the serum assay, as is the case for benign liver disease and liver metastases. For 
differentiating these tumour types, dynamic studies of alpha - fetoprotein level are 
essential. In this regard a stable or rising alpha - fetoprotein has been shown to be 
typical  of  hepatocellular  carcinoma,  an  undulating  pattern  is  characteristic  of 
cirrhosis and a wave like pattern is suggestive of viral hepatitis.
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In a study by Chen and Sung, in 60 cases of hepatocellular carcinoma, the 
tumor cell differentiation was classified according to Edmondson. Serum alpha - 
fetoprotein was detected with double diffusion in 3 out of 16 (19%) cases of the 
mature cell type (Grade I to II) and in 34 out of 44 cases (77%) of the immature 
cell  type  (Grade  III  to  IV).  The  difference  was  statistically  significant  (p  < 
0.025)46.                 
The  most  important  advantages  of  alpha  -  fetoprotein  measurement  in 
surgery is in the detection of tumour recurrence. Serial quantitative determinations 
of  serum  alpha  -  fetoprotein  provide  important  follow  up  information  on 
hepatocellular  carcinoma  patients.  A  steady  rise  in  serum  alpha  -  fetoprotein 
usually implies a tumour recurrence34.
Fucosylated  alpha -  fetoprotein is  heterogeneous in structure and has a 
difference in the oligosaccharide side chain of alpha - fetoprotein. Several reports 
have attested the usefulness of fucosylated alpha - fetoprotein in differentiating 
hepatocellular  carcinoma  from  benign  hepatic  parenchymal  lesions.  This 
refinement is particularly useful in the differential diagnosis of hepatocellular 
carcinoma when the serum alpha - fetoprotein concentration is less than 400 ng/ml 
and it may improve the diagnostic yield of alpha - fetoprotein in presymptomatic 
tumours.  Unfortunately  the  method now used to  measure  fucosylated   alpha - 
fetoprotein  is rather complex and costly30.
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OTHER SEROLOGICAL TUMOR MARKERS IN HCC :30 
Various  tumour  markers  are  being  evaluated  in  the  early  detection  of 
hepatocellular carcinoma. Their specificity and sensitivity varies.
Sensitivity      Specificity
1. Des – gamma – carboxy Prothrombin 58 – 91% 84%
2. Alpha– L – Fucosidase 75% 70 – 90%
3. CA 125 High Low
4. Tissue Polypeptide antigen High Low
5. Tumour associated isoenzymes of 
    5’ – nucleotide phosphodiseterase  High Low
6. Tumour associated iso enzymes of 
     gamma glutamyl transferase Low High
7. Variant Alkaline Phosphatase Low High
8. Ferritin Low Low
9. Carcino embryonic antigen Low Low
10. CA 19 – 9 Low Low
11. Abnormal Vit B12 binding protein Specific for fibro lamellar variant 
of  hepatocellular carcinoma 
12. Neurotensin Specific for fibro lamellar variant 
of  hepatocellular carcinoma
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IMMUNOCYTOCHEMISTRY :
Immunocytochemistry has over the years evolved into a revolutionary 
diagnostic tool for the pathologist. The necessity for some special training 
method can be recognized from the fact that surgical pathology is a subjective 
discipline. Despite the presence of various diagnostic cytologic criteria, there 
is overlapping among different entities and dissimilarities among the same 
entity. This when compounded with subjective disparity among pathologists, 
reproducibility of diagnosis becomes difficult35.
This prompted the development of special staining techniques to stain cells 
of  particular  lineage;  marking  the  beginning  of  histochemistry  in  the  mid 
nineteenth  century.  Francois  Vincent  Raspaid  is  the  earliest  botanist  to  use 
immunochemistry. Advent of aniline dyes revolutionized immunochemistry from 
1862 to 1929.
With  the  development  of  immunology,  a  new  method  of  staining  was 
developed incorporating immunological techniques. Here, antibodies labeled with 
special stains are used to identify special antigens in the tissue. Combination of 
antibody with antigen gives a complex which imparts a particular colour to the 
cells with specific antigen.
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Immunocytochemistry is an important adjunct method in cytologic 
diagnosis. The origin of immunocytochemistry techniques lies in the 
pioneering work of Albert Coons, starting in 1941. He described his first 
attempts to label antibodies directly with fluorescent isocyanate, antigens 
today are usually detected by the indirect technique introduced in 1955, that 
is, an unlabeled antibody is followed by a fluorescein or enzyme labeled 
second antibody.
The immunocytochemistry data have to be considered together with 
the other information available to the cytopathologist. 
Immunocytochemistry should never be selected as the sole or only 
method of diagnosis but must be integrated into the cytologic decision 
making process36.
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 DETECTION SYSTEM :
Subsequent to the development of specific antibodies to the antigens, 
next step for the immunochemist was to develop techniques to visualize the 
antigen antibody complex. In direct method the primary antibody is 
conjugated directly to the label. Most popular direct conjugates are those 
which are labeled with a fluorochrome, horse radish peroxidase and alkaline 
phosphates. The advantage of this method is that they are simple to use as 
they only require one application of reagent followed by appropriate 
chromogen substrate solution37.
The sensitivity of immunochemical stains was significantly improved with 
the development of an indirect technique38. This is a two step method in which 
labeled  secondary  antibody  reacts  with  the  antigen  bound  primary  antibody. 
Further increase in sensitivity over the indirect technique was achieved with the 
introduction  of  peroxide  -  anti  peroxide  enzyme complex.  In  this  method,  the 
secondary antibody serves as a linking antibody between the primary antibody and 
the  peroxide  -  antiperoxide  complex.  Subsequent  developments  exploited  the 
strong affinity of avidin for biotin and resulted in Avidin  Biotin Complex method 
of  H.S.U.et  al39.  This  technique  employs  an  enzyme  labeled  Avidin   Biotin 
Complex which is mixed prior to use and forms a complex with a biotinylated 
   ?
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secondary antibody. Avidin  Biotin Complex method increased reagent sensitivity 
when compared to the peroxide - antiperoxide reagent.
BIOTIN – STREPTAVIDIN SYSTEM :                
Avidin  Biotin  complex  (ABC)  method  is  modified  for  substituting 
streptavidin  for  Avidin.  In  comparison  to  ABC  method,  Streptavidin  Biotin 
method is four to eight times more sensitive40. Streptavidin, a tetrameric 60KD 
avidin  analog  isolated  from the  bacterium streptomyces  avidinii  is  capable  of 
binding biotin with a very high affinity. The use of streptavidin is preferred to 
avidin for several reasons.
1. Streptavidin contains no carbohydrates, which bind nonspecifically to lectin 
like substances found in normal tissue from kidney, liver, brain and mast cells.
2. The isoelectric point of streptavidin is close to neutrality, whereas avidin has 
an  isoelectric  point  of  10;  thus  streptavidin  conjugates  do  not  exhibit  the 
nonspecific electrostatic binding characteristic of avidin conjugates, which are 
positively charged under physiologic conditions.
3. Because the enzyme is directly conjugated to streptavidin in BSA system, it is 
a highly stable reagent that can be diluted and stored for long periods in a 
ready to use form31.
41
CURRENT TECHNIQUES :       
Enhanced polymer one step staining method (EPOS) is a new direct 
technique reported by Pluzek et al in 1993. In this method, a large number of 
primary antibody molecules and peroxidase enzymes are attached to a 
dextran polymer "back bone". This is rapid, can be used for frozen sections 
and sensitive enough to demonstrate small amounts of antigen.
           Dextran polymer conjugate Two Step visualization system is a new 
indirect system based on dextran technology employed in the EPOS labeling 
system. The primary antibody in the EPOS model is replaced with a 
secondary antibody. This method offers greater sensitivity than the 
traditional indirect systems, is less time consuming than the three stage 
Avidin Biotin systems and does not read with endogenous biotin37.
CURRENT APPLICATIONS OF IMMUNOCYTOCHEMISTRY :
1. Analysis of tumour origin : Generally, tumours are classified 
histogenetically (such as epithelial, mesenchymal  or neural) or by their 
origin (such as lung, breast, liver). Many antibodies recognise antigens 
that are expressed by cells of specific histogenesis. The antibodies with 
widest use are those that indicate the embryologic origin of cells.
2. To  predict  the  behavior  of  the  tumour  by  identifying  the  prognostic 
markers.      
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3. Identification of Infections : The availability of antibodies against microbial 
agents and more recently, of  nucleus acid probes targeting microbial DNA 
or RNA has bred the development of wide range of immunocytochemical 
techniques or in situ hybridisation techniques for the detection of specific 
types of organisms like HBsAg.36
ALPHA - FETOPROTEIN IN IMMUNOCYTOCHEMISTRY OF 
HEPATOCELLULAR CARCINOMA :
The finding of a hepatic tumour with immunoreactivity for alpha - 
fetoprotein is very suggestive of hepatocellular carcinomas, and its presence 
in poorly differentiated tumours may be of particular diagnostic utility(13)
In a study by C.Brumm and C.Schulze, alpha - fetoprotein  was found 
in 16/63 (24%) of hepatocellular carcinomas and in two hepatoblastomas. 
When comparing tissue positivity for alpha - fetoprotein with tumour 
differentiation, grade1 hepatocellular carcinomas were found to be negative, 
while 21% of grade 2, 36% of grade 3 and 16% of grade 4, respectively 
stained positively. alpha - fetoprotein positive cells were present in 9/10 
hepatocellular carcinomas with serum levels exceeding 5000 ng / ml, but were 
absent in 17 tumors with serum alpha - fetoprotein levels below 5000 ng / ml 
all tumours other than hepatocellular carcinomas and hepatoblastomas were 
alpha - fetoprotein negative41.
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According  to Orlos, W.M.Bedrossian and Rosa.Davila alpha - fetoprotein 
was positive in four of eight hepatocellular carcinomas and concluded that alpha - 
fetoprotein has been considered a reliable marker of hepatic origin for a tumor 
arising in the liver, provided that a germ cell neoplasm has been excluded. alpha -  
fetoprotein was immunocytochemically negative in all 41 tumours of nonhepatic 
origin that were investigated42.
In a study by Lee F.Fucich and Mary K. Cheles serum alpha - fetoprotein 
levels were elevated in four of seven patients with hepatocellular carcinoma and 
alpha  -  fetoprotein  was  expressed  immunohistochemically  in  all  four  of  these 
patients with hepatocellular carcinoma43. 
In a study by Ingebrog A. Koelma and Marius Nap, the presence of alpha - 
fetoprotein was noted in 3 cases out of 26 cases and the expression of alpha - 
fetoprotein could also be demonstrated in the series of alcoholic hepatitis (1 of 11) 
secondary biliary cirrhosis (2 of 10) and focal nodular hyperplasia (1 of 8). It  was 
negative in 15 cases of metastases to  liver44.
In a study conducted by Swan N. Thung and Michael A.Gerber, alpha - 
fetoprotein  was  detected  immunochemically  in  11  cases  (35%)  among  37 
hepatocellular carcinomas. Also Alpha – 1 antitrypsin was expressed in 73% of 
hepatocellular carcinomas. CEA was less common. HBsAg, but not HBcAg, was 
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observed in tumor cells in seven of nine hepatocellular carcinomas from HBsAg 
positive patients45.
According  to  a  study  by  Pui  Chee  Wu  and  Jane  Wing  Sang   alpha  - 
fetoprotein was detected in tumor tissue in 101 (40.9%) of the 254 patients tested.  
A higher proportion of poorly differentiated hepatocellular carcinomas expressed 
alpha  -  fetoprotein  when  compared  to  well  differentiated  Hepatocellular 
Carcinoma. Also HepPar1 reactive antigen was detected in 289 out of 290 patients 
(99.7%)47.
In  a  study  by  Fumio  Nomura  &  Kunihiko  Ohnishi  they  compared  the 
cytological  features of hepatocellular carcinomas with serum alpha - fetoprotein 
levels. A total of 606 patients were divided into four groups based on their serum 
alpha - fetoprotein levels at the time of diagnosis.
Group 1  (< 20 ng/ml) N = 125
Group 2 (20 – 1000 ng/ml) N = 256
Group 3 (1000 – 10,000 ng/ml) N = 149
Group 4 (>10,000 ng/ml) N = 76
Increasing  prevalence  of  group  1  patients  and  decreasing  prevalence  of 
group 4 were noted over a period of 9 years. And it was also noted that poorly 
differentiated tumours tend to be alpha - fetoprotein positive more often than well 
differentiated tumours48.
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In a study by Chan K. MA and Richard J.Zarbo, Alpha Feto – Protein 
was positive in 19% of hepatocellular carcinomas. This frequency is similar to 
that of most studies, and confirms lack of sensitivity of this antibody to alpha 
- fetoprotein. Yet it appears that alpha - fetoprotein is still a worthwhile 
diagnostic stain, because poorly differentiated hepatocellular carcinomas 
have a high probability of expressing alpha - fetoprotein than well 
differentiated hepatocellular carcinomas 49.
Alpha - fetoprotein disappears from the blood after birth but reappears in 
80%  to  90%  of  patients  with  hepatocellular  carcinomas.  However,  it  can  be 
demonstrated  by  immunocytochemistry  in  only  12% to  62% of  hepatocellular 
carcinoma. An alpha - fetoprotein staining is focal and most often found in the 
undifferentiated neoplasms50. Alpha - fetoprotein is a reasonably specific marker 
for  hepatocellular  carcinomas.  It  has  been  noted  to  be  absent  in  small  well 
differentiated hepatocellular carcinomas 36.
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Other immunocytochemical markers in hepatocellular carcinomas 13 :
I. Greatest Diagnostic Utility
S.NO FEATURES SENSITIVITY Comments
1
p CEA (Canalicular 
staining)
50 – 90 %
Near 100% specificity; beware 
trapped non – neoplastic hepatocytes 
and mimics of canalicular pattern in 
non – HCC; often negative in poorly 
differentiated HCC
2
m-CEA (non 
canalicular Staining)
0 – 10%
Rarely positive in HCC, 60 – 75% of 
cholangiocarcinoma metastatic 
Adenocarcinoma positive.
S.No FEATURES Sensitivity Comments
3 Hep Par – 1 80%
90% specificity, beware trapped non 
neoplastic hepatocytes rarely 
cholangiocarcinoma or metastatic 
Adeno carcinoma positive.
4 ERY – 1 90%
95% specificity, may be found in 
renal cell carcinoma, yolk sac 
tumour, transitional cell carcinoma; 
staining often focal; normal 
hepatocyte is positive.
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II. Some diagnostic utility13
S.NO FEATURES SENSITIVITY Comments
1
Hepatocyte CK (8, 
18) versus other 
cytokeratins
94 – 100
Verus 30 – 60
Lack of specificity, but of use 
if only "hepatocyte CK" 
positive.
2 CD 34 (endothelium) 50 – 100
Rare positive in cirrhotic liver : 
Prominent in advanced HCC, 
50% of small well 
differentiated hepatocellular 
carcinomas are negative
III. Least diagnostic utility and / or few data13
S.NO FEATURES SENSITIVITY Comments
1 ∝ 1 Microglobulin 95
Near 90% specificity; need 
more data
2 Albumin Nearly 100
Frequent false – positive 
results, prominent background 
staining
3 Inhibin 5 – 90
Higher rate appears to be false 
– positive, biotin not blocked
4 PTHrP 0
All CC positive, metastatic 
adenocarcinoma may be 
positive (best frozen tissue)
5 A1- AT 55 – 93
Lack of specificity and / or 
sensitivity
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6 EMA 40
Lack of specificity and / or 
sensitivity
7 B72, 3 5 – 10
Lack of specificity and / or 
sensitivity
8 Ber – EP4 35
Lack of specificity and / or 
sensitivity
S.NO FEATURES SENSITIVITY Comments
9 HMFG – Z 20
Lack of specificity and / or 
sensitivity
10 Cu – 18 10
Lack of specificity and / or 
sensitivity
11 TPA 30 (Weak)
Lack of specificity and / or 
sensitivity
12 Lau – M1 / CD 15 5 – 30
Lack of specificity and / or 
sensitivity
13 Ferritin 45 – 70
Lack of specificity and / or 
sensitivity
14 Factor XIII a 65 – 70
Lack of specificity and / or 
sensitivity
15 Synaptophysin 5 – 10
Focal positivity does not 
exclude HCC versus neuro 
endocrine tumour.
16 Chromogranin 5
Focal positivity does not 
exclude HCC versus neuro – 
endocrine tumour
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Immunocytochemistry using unabsorbed polyclonal anti CEA anti serum or 
certain monoclonal CEA (m – CEA) antibodies, each of which cross reacts with 
canalicular  biliary  glycoprotein  1,  demonstrates  bile  canaliculi  (canalicular 
pattern)  in 70% to 80% of hepatocellular carcinomas. (range 24% to 90%)50
Canalicular  CEA  staining  remains  one  of  the  most  useful  and  most 
thoroughly  investigated  immunohistochemical  markers  in  the  differential 
diagnosis of hepatocellular carcinomas, although one drawback is that this pattern 
of  immunoreactivity  is  most  frequently  seen  in  better  differentiated  tumours. 
About  50%  of  poorly  differentiated  tumours  lack  immunoreactivity.  A  false 
positive hepatocellular carcinoma interpretation of a canalicular pattern may result 
from inclusion of immunoreactive non - neoplastic hepatocytes within the tumour, 
misinterpretation of an incomplete membrane pattern as canalicular in location, or 
misinterpretation of periluminal immunoreactivity in adeno carcinomas as staining 
of  dilated  canaliculi.  cytoplasmic  immunoreactivity  with  m –  CEA antisera  is 
uncommon, and for this reason, absence of immunoreactivity with this antibody 
may be diagnostically useful50.
Hep Par – 1 is a relatively hepatocyte specific monoclonal antibody that 
reacts  with  a  hepatocyte  epitope.  Its  staining  pattern  suggests  organelle 
localization,  possibly  mitochondrial  studies  from  University  of  Pittsburgh  in 
Pennsylvania have shown performance characteristics similar to those of p – CEA 
with 82% sensitivity and 90% specificity. HepPar – 1 has been shown to be useful 
for  distinguishing  hepatocellular  carcinoma  from  cholangiocarcinoma  and 
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metastatic adeno carcinoma in most settings51 although positivity is occasionally 
found in cholangio carcinoma. HepPar – 1 is probably best used as part of a panel 
of immuno markers52.
With the availability of an array of markers the problem is in choosing one 
marker wisely. However in practice,  many investigators currently   use a  panel of 
p  – CEA (canalicular  pattern),  m – CEA, HepPar – 1 and alpha -  fetoprotein 
antibodies when evaluating diagnostically challenging cases13.
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MATERIALS   AND   METHODS  
Cases  diagnosed  as  hepatocellular  carcinoma  on  fine  needle  aspiration 
smears received in the Department of Cytology, PSG IMS & R during a period 
from December 2003 to December 2004 were taken. The slides were stained with 
Leishman’s  and  Papanicolou  stain.  These  were  graded as  low grade  and  high 
grade  as  per  the  guidelines  given  by  Martha  Bishop  Pitman  in  Diagnostic 
Cytology  of  Liver  Aspirates  in  Robert.  D.Odze's  –  Surgical  Pathology  of  the 
G.I.Iract, Liver, Biliary tract & Pancreas, First Edition.
The  unstained  slides  fixed  in  alcohol  were  used  for  running 
immunocytochemistry by using Streptavidin Biotin Complex technique.
Method :
Streptavidin Biotin Complex technique.
Antibody :
Primary antibody – polyclonal rabbit Anti Human alpha  - fetoprotein 
supplied from DAKOCYTOMATION 
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PRINCIPLE OF STREPTAVIDIN BIOTIN COMPLEX TECHNIQUE :
The high affinity of glycoprotein for biotin was harnessed in this 
technique. Originally the egg white protein avidin was used as a source of 
glycoprotein rich element. But the presence of oligosaccharides in the 
molecule made it non – specific. Hence streptavidin obtained from the culture 
broth of the bacterium streptomyces avidinii was used in the place of avidin. 
Though studies  have come giving almost equal results in both streptavidin 
and avidin in general, streptavidin is the preferred protein. Biotin has the 
ability to conjugate multiple antibodies and enzyme markers. Hence 
biotinylated enzymes like peroxidase is bound to streptavidin which forms the 
streptavidin biotin complex. This complex can now attach to large number of 
antibodies, thus increasing the sensitivity.
REAGENTS USED :
1. 3% hydrogen peroxide in water
2. Primary Antibody – polyclonal rabbit anti human alpha  - fetoprotein 
supplied from DAKO CYTOMATION.
3. TRIS buffer pH 7.4
4. DAKO labeled streptavidin biotin, horse radish peroxidase (DAKO 
LSAB 2 system, HRP)
5. Harris Haematoxylin
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6. DPX Mountant
PREPARATION OF TRIS BUFFER PH 7.4 :
1. Preparation of stock solution A (0.2 m tris) Dissolve 2.42 grams TRIS 
(Mol. Wt 121) in 100 ml of distilled water.
2. Preparation of stock solution B (0.2 m HCL)  1.7 ml of HCL (Mol. wt. 
36.46) mixed in 100 ml of distilled water.
3. Mix 30ml of solution A and 22.2 ml of solution B and made upto 100ml.
IMMUNOCYTOCHEMISTRY WAS RUN AS FOLLOWS :
1. The smears were placed in TRIS buffer pH 7.4 for 5 minutes.
2. Placed  in 3% hydrogen peroxide for 10 minutes.
3. Washed in TRIS buffer for 5 minutes. 
4. Then the slides were incubated with the primary antibody, polyclonal 
rabbit anti human alpha 1 - fetoprotein  for 30 minutes.
5. Washed in TRIS buffer for 5 minutes
6. Biotinylated secondary antibody was applied to smears for 30 minutes
7. Washed in TRIS buffer for 5 minutes
8. Slides were incubated in streptavidin biotin complex linked horse 
radish peroxidase (DAKO, LSAB, Peroxidase, DAB) for 30 minutes.
9. Washed in TRIS buffer for 5 minutes
10. DAB was used as a chromogen for 30 minutes.
11. Washed thoroughly in running tap water.
12. Smears were counterstained with Harris haemotoxylin
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13. Smears were air dried and mounted with DPX.
Tumour cells were scored positive if there was golden brown 
cytoplasmic staining in the neoplastic cells. The presence or absence of 
nuclear staining was also noted. The expression of the marker was graded 
as follows
Grade 0 = no positive cells
Grade 1 = < 1% to 24% positive
Grade 2 = 25% to 49% positive
Grade 3 = 50% to 74% positive
Grade 4 = >75% positive cells in accordance to a study by Pui  Chee Wu 
and Jane Wing  Sang in American Journal of Pathology53. 
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OBSERVATIONS
A total of 1,337 fine needle aspiration smears were reported in the 
Department of Pathology over a period of 1 year from December 2003 to 
December 2004. Out of these, 86 cases were guided fine needle aspirates of 
liver and 37 cases were reported as hepatocellular carcinoma. This worked 
out to an incidence of 42% among guided liver aspirates. The male : female 
ratio is as given in the Table I and Bar chart 
TABLE I
Age and sex incidence of hepatocellular carcinoma with its grade
Male Female
Age in 
years
Low 
Grade
High 
Grade
Total
Low 
Grade
High 
Grade
Total
< 40 - - - 1 - 1
40 - 59 2 2 4 - - -
60 - 69 3 5 8 2 1 3
≥  70 2 5 7 1 1 2
Total 19 6
From this table, we infer that out of 25 cases, 19 were males and 6 were 
females and the male : female ratio is  4 : 1 approximately. The peak age 
incidence of hepatocellular Carcinoma in PSGIMS & R in both male and 
females was around 60 – 70 years and only a single case was observed  in a 
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female aged 24 years. Out of this 25 cases, 11 were low grade (fig :1) and 14 
were high grade (fig 2, 3 and 4). 
HBsAg was positive in 2 cases out of 18 cases, amounting to 11% 
incidence. 7 cases were not evaluated for HBsAg.
Table II
HCV Status in hepatocellular carcinoma
Table II and  Pie chart analyses the incidence of HCV infection in these 25 
cases and it was found that 17 cases were positive for HCV and 8 were 
negative. Hence the incidence of HCV infection in hepatocellular carcinoma is 
68%.
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Table III
Correlation of serum alpha - fetoprotein level with hepatocellular carcinoma
Table IV
Correlation of serum alpha - fetoprotein with Low Grade and High 
Grade hepatocellular carcinoma
Table III, Table IV, pie chart and the line graph shows correlation of 
serum alpha - fetoprotein  level with the grade of hepatocellular carcinoma. 
The serum alpha - fetoprotein  was  above 400 ng/ml in 12 cases., out of 
which, 6 cases had values above 1000 ng/ml. It was also observed that out of 
these 12 cases with serum alpha - fetoprotein level more than 400ng/ml ,11 
cases turned out to be high grade hepatocellular carcinomas and 1 case was 
low grade hepatocellular carcinoma. .Thus, high grade hepatocellular 
carcinomas had high levels of serum alpha - fetoprotein (more than 400 
ng/ml)
13 cases had serum alpha - fetoprotein level less than 400 ng/ml. Of 
these 13 cases, 5 cases had values between 11.5 ng/ml and 400 ng/ml and 8 
cases had values between 5.1 ng/ml and 11.5ng/ml which is the normal value. 
Out of   8 cases which had  normal serum alpha - fetoprotein level, 7 were low 
grade hepatocellular carcinoma and 1 was high grade hepatocellular 
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carcinoma. Among the 5 cases which had values ranging between 11.5 ng/ml 
and 400 ng/ml, 3 were low grade hepatocellular carcinoma and 2 were high 
grade hepatocellular carcinoma. The correlation of serum alpha - fetoprotein 
level with the grade of hepatocellular carcinoma  was analysed with Chi-
square Distribution table.
The significance of the X2 Chi-square statistics is tested using a special 
distribution known as the Chi-square distribution. The calculated value of 
Chi-square is 11.97. The critical value given in the Chi-square table at 1% 
Level of Significance is 6.63 with one degree of freedom, that is Chi-square ,
X2  Square
0.1 = 6.63
Chi – Square> Chi – Square 0.01 
We conclude that the grade of hepatocellular carcinoma is related to 
serum alpha - fetoprotein value. Thus low grade hepatocellular carcinomas 
tend to have low levels of serum alpha - fetoprotein levels (less than 400 
ng/ml) and high grade hepatocellular carcinomas have high levels of serum 
alpha - fetoprotein (more than 400 ng/ml)
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This study also shows that 8 cases of cytologically proven hepatocellular carcinomas 
had normal serum alpha - fetoprotein levels  and 7 of these were low grade hepatocellular 
carcinomas  and 1 case was high grade hepatocellular carcinoma . In other words, low 
grade hepatocellular carcinomas may or may not express high serum levels of alpha - 
fetoprotein.
The Immunocytochemical analysis run on our slides is as given in Table V, VI line graph 
and bar diagram. The control for cellular alpha – fetoprotein expression was fetal liver(fig 
5).     
Table V
Percentage positivity of alpha – fetoprotein expression in varying differentiation of 
Hepatocellular Carcinoma
Table VI
Alpha - fetoprotein expression  in low grade and high grade Hepatocellular carcinoma
Table V shows immunocytochemical expression of Grade O to Grade 2 positivity 
in low grade hepatocellular carcinoma and Grade 3 and Grade 4 positivity in high grade 
hepatocellular carcinoma .
It is observed in table VI  that 12 cases had less than 50% cells expressing alpha - 
fetoprotein and 11  were low grade hepatocellular carcinoma (fig 6) and 1 was high grade 
hepatocellular carcinoma. 13 cases had more than 50% cells expressing alpha - fetoprotein 
and all of these were high grade hepatocellular carcinomas(fig 7,8). Thus, we understand 
that cytological expression of alpha - fetoprotein is  high  (more than 50%) in high grade  
tumours  and  low  (less  than  50%  )in  low  grade  tumours.  Thus,  immunocytochemical 
expression of alpha - fetoprotein is directly proportional to the grade of tumour.
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DISCUSSION
Hepatocellular  carcinoma  is  a  very  common  malignancy  in  all  African 
countries, south of Sahara and in South East  Asia  and is more common in males. 
Its  association  with viral  hepatitis  especially hepatitis  C virus and hepatitis  B 
virus has been well established . Serum alpha - fetoprotein levels remains the most 
useful marker for  hepatocellular carcinoma  (positive in 70% of cases) and levels 
above 400 ng/ml are indicative of malignancy and above 1000 ng/ml are definite 
for  hepatocellular  carcinoma33.  It  was  also  noted  that  immunocytochemical 
expression of alpha – fetoprotein in aspiration samples was directly proportional 
to the grade of hepatocellular carcinoma.
In  our  study  it  was  observed  that  males  were  commonly  affected  than 
females and the male: female ratio was 4:1. The peak age incidence for both sexes 
was between 60 to 70 years. Only one case was observed in a young female aged 
24 years.
Ikeda et al, after a fifteen year observation period reported the development 
rate of hepatocellular carcinoma as 75% for HCV and 25% for HBV infection. 
The current study shows similar trends.  68% of hepatocellular carcinomas were 
HCV positive while 11% of hepatocellular carcinomas were HBV positive. The 
declining incidence of HBV associated hepatocellular carcinoma could be due to 
the mass vaccination programmes.
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The normal serum alpha – feto protein level in adults ranges from 5.1 to 
11.5 ng/ml.  Values greater than 10 ng/ml are noted in most of the diseases of the 
liver.  Ding  and  Juei  studied  serum alpha  –  fetoprotein  levels  in  various  liver 
diseases46.  They observed values between 10 to 400 ng/ml in most of the non-
neoplastic lesions (34% in cirrhosis, 58% in chronic hepatitis and in 3 out of 13 
cases in healthy HbsAg carriers, etc.,)
They also observed that  serum alpha -  fetoprotein was greater than 400 
ng/ml in 86 out of 125 cases (69%) of hepatocellular carcinoma.
In our study,  the serum alpha -  fetoprotein was above 400 ng/ml in 12 
cases(48%). Out of these, 11 cases were high grade hepatocellular carcinoma and 
1 was low grade hepatocellular carcinoma.
The serum alpha -  fetoprotein  was  below 400ng/ml  in  13  cases,  out  of 
which 10 cases were low grade hepatocellular carcinoma and 3 were high grade 
hepatocellular carcinoma. On testing the significance of association between grade 
of hepatocellular carcinoma and serum alpha - fetoprotein level, it was observed 
that the critical value given in the Chi – square table at 1% Level of Significance is 
6.63  with  One  degree  of  freedom.  Thus,  it  can  be  concluded  that  low  grade 
hepatocellular carcinoma  tend to have low serum alpha - fetoprotein values (<400 
ng/ml)  and  high  grade  hepatocellular  carcinomas  had  high  serum  alpha  - 
fetoprotein  values (>400 ng/ml).
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In  a  study  by  Fumio  Nomura  &  Kunihiko  Ohnishi  they  compared  the 
cytological  features of hepatocellular carcinoma with serum alpha -  fetoprotein 
levels. A total of 606 patients were divided into four groups based on their serum 
alpha – fetoprotein levels at the time of diagnosis.
Group 1  (< 20 ng/ml) N = 125
Group 2 (20 – 1000 ng/ml) N = 256
Group 3 (1000 – 10,000 ng/ml) N = 149
Group 4 (>10,000 ng/ml) N = 76
Increasing  prevalence  of  group  1  patients  and  decreasing  prevalence  of 
group 4 were noted over a period of 9 years. And it was also noted that poorly 
differentiated tumours tend to be alpha – fetoprotein positive more often than well 
– differentiated tumours.
C.Brumm and C.Schulze on comparing tissue positivity for  alpha -  fetoprotein 
with tumour differentiation, they found that,
Grade 1 - 27% Negative
Grade 2 - 21% Positive
Grade 3 - 36% Positive
Grade 4 - 16% Positive
Alpha  -  fetoprotein  positive  cells  were  present  in  9/10  hepatocellular 
carcinoma with serum levels exceeding 5000 ng/ml but were absent in 17 tumours 
with serum alpha - fetoprotein levels below 5000 ng/ml41.
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According  to  a  study  by  Pui   Chee  Wu  and  Jane  Wing  Sang  alpha  - 
fetoprotein expression was graded as follows ,
Grade O - No Positive Cells
Grade 1 - <1 to 24% Positive
Grade 2 - 25 to 49% Positive
Grade 3 - 50 to 74% Positive
Grade 4 - ≥  75% Positive cells
Alpha – fetoprotein was detected in tumor cells in 101 patients (40.9%) of the 254 
patients  tested.  A  higher  proportion  of  poorly  differentiated  hepatocellular 
carcinoma expressed  alpha  -  fetoprotein  when compared to  well  differentiated 
hepatocellular carcinoma. Also HepPar 1 reactive antigen was detected in 289 out 
of 290 patients (99.7%)47.
According  to Orlos, W.M.Bedrossian and Rosa Davila, alpha - fetoprotein 
was positive in four of eight hepatocellular carcinomas and concluded that alpha - 
fetoprotein has been considered a reliable marker of hepatic origin for a tumor 
arising in the liver, provided that a germ cell neoplasm has been excluded. alpha -  
fetoprotein was immunocytochemically negative in all 41 tumours of nonhepatic 
origin that were investigated42.
In a study by Chan K. MA and Richard J.Zarbo, alpha - fetoprotein 
was positive in 19% of hepatocellular carcinomas. This frequency is similar to 
that of most studies, and confirms lack of sensitivity of this antibody to alpha 
- fetoprotein. Yet it appears that alpha - fetoprotein is still a worthwhile 
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diagnostic stain, because poorly differentiated hepatocellular carcinomas 
have a high probability of expressing alpha - fetoprotein than well 
differentiated hepatocellular carcinomas 49.
In our study, immunocytochemistry run on the alcohol fixed slides showed that 
alpha - fetoprotein expression was less than 50% in 12 cases, out of which 11 
cases (91%) were low grade hepatocellular carcinoma and 1 case (9%) was high 
grade hepatocellular carcinomas. Thus, in low grade hepatocellular carcinomas 
the alpha - fetoprotein expression was found to be less than 50%. On the other 
hand, all the 13 cases (100%) that had more than 50% of cells expressing alpha 
- fetoprotein were high grade hepatocellular carcinomas. Thus, high grade 
hepatocellular carcinoma had higher percentage of expression of alpha - 
fetoprotein . Hence, it was observed that immunocytochemical expression of 
alpha - fetoprotein was directly proportional to the grade of differentiation of 
hepatocellular carcinomas.
CLINICAL, SEROLOGICAL FINDINGS AND CYTOLOGICAL 
EXPRESSION IN THE PATIENTS STUDIED
Characteristics Data
Number of Patients 25
Male : Female 4 :1
Mean Age (Range) 65 (60 to 70)
HBsAg Positive 11%
HCV Positive 68%
Differentiation
a) Low Grade 
b)  High Grade
11 
14
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Characteristics Data
Serum alpha - fetoprotein
1. Less than 400 ng/ml
Total
(a) Low Grade
(b) High Grade
2. More than 400 ng/ml
Total
(a) Low Grade
(b) High Grade
13 Cases
10 Cases
3 Cases
12 Cases
1 Case
11 Cases
Cytological Expression of alpha - 
fetoprotein
1. Number of Positive Cases
2. Less than 50% Expression
(a) Low Grade
(b) High Grade
3. More than 50% Expression
(a) Low Grade
(b) High Grade
         22 Cases (88%)
12 Cases
11 Cases
1 Case
13 Cases
0
13 Cases
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SUMMARY AND  CONCLUSION
Hepatocellular carcinoma is one of the most common malignancies and 
is a leading cause of  cancer related death  in developing countries. The 
incidence of hepatocellular carcinoma was found to be 42% among guided 
liver aspirates at PSG IMS & R. 
 The purpose of this study was to determine whether alpha - fetoprotein 
could be used to aid in the diagnosis of hepatocellular Carcinoma and to 
correlate the percentage positivity of cytological alpha - fetoprotein 
expression with the differentiation of hepatocellular carcinoma. Also the 
serological factors such as serum alpha - fetoprotein level, HBsAg and HCV 
status were correlated. To evaluate the above factors, 25 cases of cytologically 
diagnosed hepatocellular carcinomas were chosen and the slides were stained 
using Streptavidin Biotin complex method with DAB as chromogen. The 
cytological alpha - fetoprotein  expression was then studied.
It was observed that alpha - fetoprotein  was expressed cytologically in 
88%(22 cases) of hepatocellular carcinomas. Thus alpha - fetoprotein staining 
is 
helpful if positive, but a  negative  stain  in  no  way  rules out  the  presence 
of   a 
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tumour. Also all  the 3 tumours that were negative for alpha - fetoprotein 
staining were cytologically low grade hepatocellular carcinomas. Thus low 
grade tumours tend to be negative for alpha - fetoprotein.           
                The percentage of cells expressing alpha - fetoprotein increased in 
relation to the grade of differentiation. All the low grade hepatocellular 
carcinomas (100%)  which had positive staining showed less than 50 % of the 
cells to be positive and 92 % of high grade hepatocellular carcinomas that 
had positive staining showed more than 50% of the cells to be positive. Thus 
it was observed that the expression of alpha - fetoprotein was directly 
proportional to the grade of tumour, i.e., high grade tumours show higher 
percentage of expression.
The cytological grading also correlated well with serum alpha - 
fetoprotein level as per Chi – Square distribution table concluding that high 
grade hepatocellular carcinoma had higher serum alpha - fetoprotein value 
(more than 400 ng/ml) and low grade hepatocellular carcinoma has lower 
serum alpha – fetoprotein value (less than 400 ng / ml).
The incidence of HBsAg and HCV infection was found to be 11% and 
68% respectively in the hepatocellular carcinomas.
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 CONCLUSIONS 
1. Alpha - fetoprotein is  a reliable immunocytochemical marker for 
hepatocellular carcinoma.
2. The expression of alpha - fetoprotein in the cells was found to be 
directly proportional to the grade of hepatocellular carcinoma.
            Further studies with more number of cases can be done to prove 
that this might be a useful marker to differentiate between  low  grade 
and high grade hepatocellular carcinoma cases.
           Also, alpha - fetoprotein  can be included among a panel of other 
known markers like HepPar 1, p – CEA and m– CEA in diagnosis of 
hepatocellular carcinoma and the contribution by each of these 
markers in all cases can be evaluated and diagnostic accuracy can be 
enhanced.
3. Serum alpha - fetoprotein level is also related to the grade of 
hepatocellular carcinoma. Levels more than 400 ng/ml are common in 
high grade hepatocellular carcinoma.
4. HCV is more often associated with hepatocellular carcinoma (68%) 
than HBV (11%).
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